Table 1.
Subsequent therapy in patients who received ribociclib plus fulvestrant as first-line therapy
| Parameter, n (%) | Ribociclib + Fulvestrant n = 237 | Placebo + Fulvestrant n = 128 |
|---|---|---|
| Patients who discontinued study treatment | 198 (83.5) | 117 (91.4) |
| Patients who received first subsequent antineoplastic therapy | 162 (81.8) | 105 (89.7) |
| Chemotherapy alone | 25 (12.6) | 19 (16.2) |
| Chemotherapy + hormonal or other therapya | 16 (8.1) | 15 (12.8) |
| Hormonal therapy alone | 71 (35.9) | 30 (25.6) |
| Hormonal therapy + targeted or other therapyb | 45 (22.7) | 40 (34.2) |
| Targeted therapy alone or other therapy | 5 (2.5) | 1 (0.9) |
| Patients who received a CDK4/6i in any subsequent line of therapy | 33 (16.7) | 41 (35.0) |
| Palbociclib | 17 (8.6) | 32 (27.4) |
| Ribociclib | 13 (6.6) | 7 (6.0) |
| Abemaciclib | 6 (3.0) | 3 (2.6) |
aIncludes patients who received chemotherapy in combination with any non-chemotherapy
bIncludes patients who received hormonal therapy + other therapy without chemotherapy